Lutetium (177Lu) vipivotide tetraxetan (Pluvicto®)

Assessment Status Rapid Review Complete
HTA ID 23002
Drug Lutetium (177Lu) vipivotide tetraxetan
Brand Pluvicto®
Assessment Process
Rapid review commissioned 09/01/2023
Rapid review completed 10/02/2023
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of Lutetium (177Lu) vipivotide tetraxetan (Pluvicto®) compared with the current standard of care.